Loading
The current WHO scheme for thymic tumours, which keeps the type A to B3 thymoma letters and the separate category of thymic carcinoma while adding new molecular entities.
Summary by members of the WHO editorial board of the fifth-edition classification of thymic and mediastinal tumours: thymoma types A, AB, B1, B2 and B3 and their rarer variants, thymic carcinomas (squamous, basaloid, mucoepidermoid, lymphoepithelial, NUT carcinoma and others), thymic neuroendocrine neoplasms, and mediastinal germ cell and mesenchymal tumours.
It highlights immunohistochemical and molecular markers (such as GTF2I mutations in type A and AB thymomas and NUTM1 fusions in NUT carcinoma), the requirement to report all thymomas as malignant, and the alignment with TNM staging.
The names on a thymic pathology report, and the sharp line between thymoma and thymic carcinoma that drives treatment, come from this classification.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3).
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3).
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3).
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3).
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3).
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3).
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3).
Shares Mediastinal germ cell tumour, Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3).